论文部分内容阅读
目的探讨布地奈德混悬液联合孟鲁司特钠片治疗支气管哮喘的临床疗效。方法选取2012—2013年德阳市东汽医院收治的支气管哮喘患者78例,随机分成治疗组和对照组,每组39例。对照组给予布地奈德治疗,治疗组给予布地奈德联合孟鲁司特钠治疗。比较两组患者的临床疗效、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气高峰流量(PEFR)。结果治疗前两组患者的FEV1、FVC和PEFR比较,差异无统计学意义(P>0.05);治疗后治疗组FEV1、FVE和PEFR高于对照组,差异有统计学意义(P<0.05)。治疗组总有效率高于对照组,差异有统计学意义(P<0.05)。结论布地奈德混悬液联合孟鲁司特钠片治疗支气管哮喘的临床疗效显著,可有效改善患者肺功能,且不良反应少。
Objective To investigate the clinical efficacy of budesonide suspension combined with montelukast sodium in the treatment of bronchial asthma. Methods 78 patients with bronchial asthma admitted to Dongqi Hospital of Deyang from 2012 to 2013 were randomly divided into treatment group and control group, with 39 cases in each group. The control group received budesonide, and the treatment group received budesonide combined with montelukast sodium. The clinical efficacy, FEV1, FVC, and peak expiratory flow (PEFR) were compared between the two groups. Results There was no significant difference in FEV1, FVC and PEFR between the two groups before treatment (P> 0.05). After treatment, the FEV1, FVE and PEFR in the treatment group were significantly higher than those in the control group (P <0.05). The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05). Conclusions Budesonide suspension combined with montelukast sodium tablets in the treatment of bronchial asthma significantly clinical efficacy, can effectively improve lung function in patients with less adverse reactions.